Cary, North Carolina — Focal Medical, Inc., (“Focal”) a privately held biopharmaceutical company developing a targeted therapeutic system to treat inoperable tumors and to deliver genomic medicines, today announced that it has received a $300,000 award from the National Cancer…
Ness Bermingham, Ph.D. Khosla Ventures partner and Intellia Therapeutics founder, joins Board. Advance of IOP cisplatin for locally recurrent oral cavity cancer into formal development. Cary, North Carolina, January 30, 2024 — Focal Medical, Inc., (“Focal”) a Khosla Ventures backed…
ACT-IOP-003 is an implantable iontophoretic product designed to safely achieve high concentration of gemcitabine in the pancreas, via non-circulatory pathways and with little to no systemic drug exposure or associated toxicity. Demonstrated dramatic results in an orthotopic patient-derived xenograft murine…
Developed a laparoscopic surgical technique to enable the minimally invasive implantation of ACT-IOP-003 device onto the pancreas. ACT-IOP-003, Focal Medical’s targeted therapeutic product, is designed to safely achieve a high concentration of chemotherapeutic in the target organ, via non-circulatory pathways,…
Trial & Enrollment Details Cary, NC and Roanoke, VA, May 04, 2023 — Focal Medical, Inc., a privately held, biopharmaceutical company developing novel therapeutic products based on its innovative local drug delivery technology platform today announced the initiation of…
